Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

341 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Discovery of remogliflozin etabonate: A potent and highly selective SGLT2 inhibitor.
Shimizu K, Fujikura H, Fushimi N, Nishimura T, Tatani K, Katsuno K, Fujimori Y, Watanabe S, Hiratochi M, Nakabayashi T, Kamada N, Arakawa K, Hikawa H, Azumaya I, Isaji M. Shimizu K, et al. Among authors: nakabayashi t. Bioorg Med Chem. 2021 Mar 15;34:116033. doi: 10.1016/j.bmc.2021.116033. Epub 2021 Jan 22. Bioorg Med Chem. 2021. PMID: 33581390
Structure-activity relationship studies of 4-benzyl-1H-pyrazol-3-yl β-d-glucopyranoside derivatives as potent and selective sodium glucose co-transporter 1 (SGLT1) inhibitors with therapeutic activity on postprandial hyperglycemia.
Fushimi N, Fujikura H, Shiohara H, Teranishi H, Shimizu K, Yonekubo S, Ohno K, Miyagi T, Itoh F, Shibazaki T, Tomae M, Ishikawa-Takemura Y, Nakabayashi T, Kamada N, Ozawa T, Kobayashi S, Isaji M. Fushimi N, et al. Among authors: nakabayashi t. Bioorg Med Chem. 2012 Nov 15;20(22):6598-612. doi: 10.1016/j.bmc.2012.09.037. Epub 2012 Sep 24. Bioorg Med Chem. 2012. PMID: 23062824
Design, synthesis, and structure-activity relationships of a series of 4-benzyl-5-isopropyl-1H-pyrazol-3-yl β-D-glycopyranosides substituted with novel hydrophilic groups as highly potent inhibitors of sodium glucose co-transporter 1 (SGLT1).
Fushimi N, Teranishi H, Shimizu K, Yonekubo S, Ohno K, Miyagi T, Itoh F, Shibazaki T, Tomae M, Ishikawa-Takemura Y, Nakabayashi T, Kamada N, Yamauchi Y, Kobayashi S, Isaji M. Fushimi N, et al. Among authors: nakabayashi t. Bioorg Med Chem. 2013 Feb 1;21(3):748-65. doi: 10.1016/j.bmc.2012.11.041. Epub 2012 Dec 5. Bioorg Med Chem. 2013. PMID: 23273606
Guideline for evaluating the effects of psychotropic drugs on motor vehicle driving performance in Japan: A tiered approach for the assessment of clinically meaningful driving impairment.
Nakabayashi T, Iwamoto K, Yamaguchi A, Konishi Y, Saji M, Yoshimura R, Kanemoto K, Aoki H, Ando M, Ozaki N. Nakabayashi T, et al. Neuropsychopharmacol Rep. 2024 Apr 16. doi: 10.1002/npr2.12436. Online ahead of print. Neuropsychopharmacol Rep. 2024. PMID: 38624143 Free article. Review.
Metagenomic gut microbiome analysis of Japanese patients with multiple chemical sensitivity/idiopathic environmental intolerance.
Watai K, Suda W, Kurokawa R, Sekiya K, Hayashi H, Iwata M, Nagayama K, Nakamura Y, Hamada Y, Kamide Y, Fukutomi Y, Nakabayashi T, Tanaka K, Kamita M, Taniguchi M, Hattori M. Watai K, et al. Among authors: nakabayashi t. BMC Microbiol. 2024 Mar 11;24(1):84. doi: 10.1186/s12866-024-03239-y. BMC Microbiol. 2024. PMID: 38468206 Free PMC article.
341 results